Pharmacologic Treatment of Oscillopsia from Nystagmus

This is an old revision of the document!

Recommendation depends on the type of nystagmus since drug efficacy differs substantially between nystagmus types.
Evidence base is limited (small crossover RCTs and case series, mostly very low-certainty)
Treatment is symptomatic—aimed at reducing slow-phase eye velocity to improve visual acuity and abolish illusory motion
No agent reliably abolishes nystagmus, effect sizes are modest, and most data come from very small studies—so treatment is often individualized with trial-and-error
Monitoring for ataxia, fatigue, and dizziness

Often from multiple sclerosis or oculopalatal tremor:

Gabapentin (typically up to ~2400 mg/day; trial doses 300 mg four times daily)
Memantine (up to 40–60 mg/day)
- In a 47-patient placebo-controlled trial gabapetin and memantine were superior to placebo and improved visual acuity, and a double-masked crossover trial found both effective at reducing eye speed and improving acuity, with individual patients responding better to one or the other.[3][2]
- Gabapentin is generally preferred first-line on tolerability grounds—memantine caused more discontinuations (18.8% vs 6.7%) and can exacerbate MS symptoms, whereas gabapentin was better tolerated.[4][2]
Topiramate (e.g., 50 mg twice daily) has produced dramatic improvement in refractory APN in a case report when gabapentin/memantine were only partially effective.[5]
Anticholinergics (trihexyphenidyl, transdermal scopolamine) are largely ineffective and not recommended; results have been inconsistent.[3][2]

Titrate up over 1-3 weeks
- Start low (e.g., 300 mg/day) and increase every few days as tolerated toward 1,200 mg/day divided TID–QID, going higher (up to ~2,400 mg/day) if partial response and well tolerated.
- In refractory cases doses as high as 1,800 mg three times daily have been used before adding another agent.
Target doses: ranged from 900 mg/day up to 2,400 mg/day
- Thurtell crossover trial used1,200 mg/day
- Nerrant trial used **300 mg four times daily (1,200 mg/day)
- EFNS review cites benefit at doses up to 2,400 mg/day
- Averbuch-Heller trial used up to 900 mg/day
Renal dosing:
- gabapentin is renally cleared and requires dose reduction in renal impairment (a critical safety point in older or MS patients with bladder/renal issues).
Key adverse effects/monitoring
- Unsteadiness/ataxia is the main dose-limiting effect—especially in patients with pre-existing cerebellar ataxia
- Somnolence, dizziness, and peripheral edema.
- Monitor gait and sedation at each titration step;
- Overall it was the better-tolerated drug, with only ~6.7% discontinuing

Titrate up over 1-3 weeks
- Conventional approach is to start 5 mg/day and increase by 5 mg/week to 20 mg/day
- Further escalation toward 40 (to 60) mg/day is done gradually and only as tolerated
- Target doses studied
  - 40 mg/day in most trials (Thurtell, EFNS)
  - 10 mg four times daily (40 mg/day) in Nerrant
  - 40–60 mg/day in the Starck MS study, where 60 mg added benefit in some patients.
  - Note these exceed the standard Alzheimer maximum of 20 mg/day, so higher doses are off-label and titrated cautiously
Renal dosing: reduce dose in severe renal impairment.
Key adverse effects/monitoring
- Lethargy and drowsiness are most common
- Dizziness, confusion, and headache
- Discontinuation was higher than gabapentin (~18.8%, including one serious adverse event).
- In MS: may worsen MS symptoms and cognition in MS patients gabapentin is preferred first-line, and if memantine is used, select patients without significant cognitive impairment and titrate cautiously

Efficacy endpoints
- Near and distance visual acuity
- Patient-reported oscillopsia
- Reduction on eye-movement recording/EOG when available.
- Trials targeted a ≥50% reduction in nystagmus amplitude/frequency
Tolerability
- Assess gait/ataxia, sedation, and cognition at each dose step;
- Renal function guides dosing for both drugs.
Approach
- do an individual trial of one drug, then the other (and sometimes combination or dose reduction to minimize side effects)
- Effects appear within the ~2-week windows used in trials, so each agent can be assessed over a few weeks

Parameter	Gabapentin	Memantine
Starting dose	300 mg/day	5 mg/day
Titration	↑ every few days as tolerated	↑ 5 mg/week
Target dose	1,200 mg/day (up to 2,400) divided TID–QID	40 mg/day (up to 60)
Main adverse effects	Ataxia/unsteadiness, somnolence, edema	Lethargy/drowsiness, dizziness, confusion
Discontinuation rate	~6.7%	~18.8%
Renal impairment	Dose reduce	Dose reduce (severe)
MS-specific caution	Preferred first-line	May worsen MS symptoms/cognition

Aminopyridines
- 4-aminopyridine (potassium channel blocker)
- 3,4-diaminopyridine
- Reduce slow-phase velocity and oscillopsia (two RCTs support use), with 4-AP possibly more potent;
- the main side effect is transient perioral/distal paresthesia.[1][6]

Nystagmus type	Preferred agent(s)	Typical dosing	Evidence/notes
Acquired pendular (MS, OPT)	Gabapentin (1st line)	Up to 2400 mg/day	Superior to placebo, better tolerated
Acquired pendular (MS, OPT)	Memantine	Up to 40-60 mg/day	Superior to placebo, Topiramate for refractory cases
Downbeat / upbeat	Aminopyridines (4-AP, 3,4-DAP)	10-20 mg	Reduce slow phase velocity, paresthesia common
Jerk	Memantine	up to 40-60 mg/day	Greater response than gabapentin in crossover trial
Periodic alternating	Baclofen	up to 30 mg/day	Agent of Choice